XHKG
1717
Market cap297mUSD
Jul 09, Last price
1.31HKD
1D
5.65%
1Q
-25.14%
Jan 2017
-57.61%
IPO
-73.37%
Name
Ausnutria Dairy Corp Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ausnutria Dairy Corporation Ltd, an investment holding firm, is primarily involved in the entire lifecycle of infant formula and other dairy products, encompassing research and development, milk sourcing, processing, manufacturing, packaging, marketing, and distribution. Its operations are divided into two main divisions: Dairy and Related Products, and Nutrition Products. The company markets cow milk-based formula products under brand names such as Allnutria, Hyproca Hollary, Hyproca Hypure, Neolac, and Puredo. Additionally, its goat milk-based infant formula is sold under the Kabrita brand. Ausnutria also functions as an original equipment manufacturer (OEM) for formula milk powder products. Beyond dairy, it manufactures and distributes various nutrition products, develops and sells probiotic items, and offers financing solutions. Its global footprint spans the People's Republic of China, the European Union, Southeast Asia, Australia, New Zealand, the Middle East, North and South America, and other international markets. Established in 2003, Ausnutria Dairy Corporation Ltd is headquartered in Sheung Wan, Hong Kong, and operates as a subsidiary of HongKong Jingang Trade Holding Company Limited.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||